engleski

Tomography Metabolic Imaging in Patients with Lymphoma

Fluorine-18 fluordeoxyglucose (FDG) provides unique information about the metabolic behavior of the malignant diseases, independent of morphological criteria. This technique is more sensitive in imaging lymphoma prior to therapy than conventional computed tomography imaging and Ga-67 scintigraphy. FDG-positron emission tomography (PET) performed in lymphoma patients with residual masses offers important additional information regarding the presence of viable disease in these residual lesions. It has also been shown to be of great value in assessing therapy response in patients with Hodgkin&#8217 ; ; s disease and non-Hodgkin&#8217 ; ; s lymphoma, because of its ability to use increased glycolysis to differentiate between fibrosis and active tumor. More studies are needed do assess the value of this method in long-term follow-up. In our institution we use this method mostly for clarification of residual post-therapy abnormalities that fall under the category of unconfirmed/uncertain complete remission. Our preliminary data in 14 patients indicate that this non-invasive metabolic imaging performed with &#8220 ; ; hybrid&#8221 ; ; coincidence technology is superior to CT and other conventional diagnostic methods in the post- therapy staging of lymphoma.

fluorodeoxyglucose F-18; Hodgkin disease; lymphoma; non-Hodgkin; tomography; emission computed

nije evidentirano